BioPharma Resources

Drug Trial Radar · NCT05508906

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Aug 31, 2022

Primary completion

Dec 31, 2027

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Olema Oncology, Inc.Industry
Sponsor type
Industry
Collaborators
Novartis; Pfizer
First posted
Aug 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b open-label, 2-part study in 4 treatment groups. The 4 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) in combination with everolimus. Treatment Group 4: Palazestrant (OP-1250) in combination with atirmociclib.

Conditions

  • Metastatic Breast Cancer
  • ER-positive Breast Cancer
  • HER2-negative Breast Cancer
  • Breast Cancer
  • Locally Advanced Breast Cancer

Interventions

  • PalazestrantDrug

    Complete estrogen receptor antagonist (CERAN)

  • RibociclibDrug

    All subjects in Treatment Group 1 will receive palazestrant in combination with ribociclib.

  • AlpelisibDrug

    All subjects in Treatment Group 2 will receive palazestrant in combination with alpelisib.

  • EverolimusDrug

    All subjects in Treatment Group 3 will receive palazestrant in combination with everolimus.

  • AtirmociclibDrug

    All subjects in Treatment Group 4 will receive palazestrant in combination with atirmociclib.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLTs)Time frame: The first 28 days of treatment
  2. Characterize the incidence, nature and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of palazestrant when administered with ribociclib, alpelisib, everolimus, or atirmociclib.Time frame: Up to 30 days after last dose of study drug(s) treatment
  3. Pharmacokinetics (PK) of palazestrant when administered with ribociclib (Treatment Group 1) or alpelisib (Treatment Group 2), everolimus (Treatment Group 3), or atirmociclib (Treatment Group 4) .Time frame: Every 28 days

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • University of California San Francisco Health

    San Francisco, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Advent Health Hematology and Oncology

    Orlando, Florida

  • University of Iowa

    Iowa City, Iowa

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Health

    Detroit, Michigan

  • Regents of the University of Minnesota

    Minneapolis, Minnesota

  • Washington University, School of Medicine

    St Louis, Missouri

  • Ichan School of Medicine at Mount Sinai

    New York, New York

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Northwest Medical Specialties

    Tacoma, Washington

  • Macquarie Health

    Sydney, New South Wales, Australia

  • Breast Cancer Research Center- Western Australia

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.